HALOZYME THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
HALOZYME THERAPEUTICS, INC. (HALO) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number of 4.86 million shares as of 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber · last filed 2026-02-17
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 4.86M shares.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 5.48M shares.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 6.42M shares.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 5.37M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number as first filed |
|---|---|---|
| 2025-12-31 | 4.86M shares 10-K · filed 2026-02-17 | |
| 2024-12-31 | 5.48M shares 10-K · filed 2026-02-17 | |
| 2023-12-31 | 6.42M shares 10-K · filed 2025-02-18 | |
| 2022-12-31 | 5.37M shares 10-K · filed 2024-02-20 | |
| 2021-12-31 | 4.97M shares 10-K · filed 2023-02-21 | |
| 2020-12-31 | 5.63M shares 10-K · filed 2022-02-22 | |
| 2019-12-31 | 11.55M shares 10-K · filed 2021-02-23 | |
| 2018-12-31 | 11.01M shares 10-K · filed 2020-02-24 | |
| 2018-09-30 | 13.40M shares 10-Q · filed 2018-11-06 | |
| 2018-06-30 | 13.80M shares 10-Q · filed 2018-08-07 | |
| 2018-03-31 | 14.10M shares 10-Q · filed 2018-05-10 | |
| 2017-12-31 | 11.11M shares 10-K · filed 2019-02-21 | |
| 2017-09-30 | 14.30M shares 10-Q · filed 2017-11-07 | |
| 2017-06-30 | 14.70M shares 10-Q · filed 2017-08-08 | |
| 2017-03-31 | 15.50M shares 10-Q · filed 2017-05-09 | |
| 2016-12-31 | 11.09M shares 10-K · filed 2019-02-21 | |
| 2016-09-30 | 12.40M shares 10-Q · filed 2016-11-07 | |
| 2016-06-30 | 11.80M shares 10-Q · filed 2016-08-09 | |
| 2016-03-31 | 11.80M shares 10-Q · filed 2016-05-09 | |
| 2015-12-31 | 7.99M shares 10-K · filed 2019-02-21 | |
| 2015-09-30 | 8.80M shares 10-Q · filed 2015-11-09 | |
| 2015-06-30 | 8.30M shares 10-Q · filed 2015-08-10 | |
| 2015-03-31 | 8.10M shares 10-Q · filed 2015-05-11 | |
| 2014-12-31 | 6.35M shares 10-K · filed 2018-02-20 | |
| 2014-09-30 | 8.40M shares 10-Q · filed 2014-11-10 | |
| 2014-06-30 | 8.40M shares 10-Q · filed 2014-08-11 | |
| 2014-03-31 | 8.70M shares 10-Q · filed 2014-05-12 | |
| 2013-12-31 | 6.70M shares 10-K · filed 2017-02-28 | |
| 2013-09-30 | 7.90M shares 10-Q · filed 2013-11-08 | |
| 2013-06-30 | 9.20M shares 10-Q · filed 2013-08-07 | |
| 2013-03-31 | 8.50M shares 10-Q · filed 2013-05-08 | |
| 2012-12-31 | 6.38M shares 10-K · filed 2016-02-29 | |
| 2012-09-30 | 6.90M shares 10-Q · filed 2012-11-08 | |
| 2012-06-30 | 6.90M shares 10-Q · filed 2012-08-09 | |
| 2011-12-31 | 5.87M shares 10-K · filed 2015-03-02 | 6.00M shares 10-Q · filed 2012-08-09 |
| 2010-12-31 | 7.98M shares 10-K · filed 2014-02-28 | |
| 2009-12-31 | 7.80M shares 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |